Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
Panelists discuss the optimal timing of chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), which requires careful evaluation of patient fitness, disease burden, prior treatment response, and logistical factors. Key considerations include performance status, comorbidities, disease aggressiveness, and the availability of bridging therapy. Treatment decisions should be individualized based on patient-specific risk factors, prior therapy outcomes, and care goals while balancing the potential benefits and risks across different lines of treatment.
EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy
EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL
EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
EP: 7.Personalizing CAR T: Making the Right Call for Each Patient
EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?
EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care
Video content above is prompted by the following:
- What factors should be considered when determining the optimal timing and patient selection for advanced therapies like chimeric antigen receptor T-cell therapy in relapsed/refractory DLBCL?
- How might you consider treatment decisions for patients across different risk profiles and lines of therapy?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
